文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

严重急性呼吸窘迫综合征患者接受静脉-静脉体外膜氧合支持的长期生存与健康相关生活质量

Long-term survival and health-related quality of life in patients with severe acute respiratory distress syndrome and veno-venous extracorporeal membrane oxygenation support.
PubMed 文献 · Crit Care · 2021-11-29
一句话结论严重ARDS接受VV ECMO的住院幸存者长期生存率与健康相关生活质量较好,6个月和12个月生存率分别为89%和85%。

该研究为德国弗莱堡大学医学中心单中心回顾性注册数据,纳入2010年10月至2019年6月因严重ARDS接受VV ECMO治疗的患者289例,随访截至2020年2月至9月。住院生存率为45%,中位随访3.9年后,129例住院幸存者中94例完成随访评估(73%),53例完成健康相关生活质量评估。住院幸存者6个月和12个月生存率分别为89%和85%,ICU存活出院者9.7年估计生存率为68.5%(95%CI 56.9-80.1%);患者报告较高的健康相关生活质量(SF-36总分中位数73),肺功能(SGRQ总分中位数19)及心理(HAD-D中位数2,HAD-A中位数3)受限较少,80%的患者能够恢复工作。作者认为这些结果提示VV ECMO幸存者长期预后较好。

要点

  • 严重ARDS接受VV ECMO治疗的患者住院生存率为45%,住院幸存者6个月和12个月生存率分别为89%和85%。
  • ICU存活出院者9.7年估计生存率为68.5%(95%CI 56.9-80.1%)。
  • 完成HRQL评估的53例患者报告较高的健康相关生活质量,SF-36总分中位数73。
  • 患者肺功能及心理受限较少:SGRQ总分中位数19,HAD-D中位数2,HAD-A中位数3。
  • 80%的患者能够恢复工作。

适用人群与场景

  • 2010年10月至2019年6月在德国弗莱堡大学医学中心跨学科内科重症监护病房接受VV ECMO治疗的严重ARDS患者289例(中位年龄55岁,67%为男性)。
  • 随访对象为住院幸存者,随访时间为2020年2月至2020年9月。

研究设计与关键结果

  • 研究类型:单中心回顾性注册数据分析;纳入289例接受VV ECMO治疗的严重ARDS患者,中位年龄55岁,67%为男性,住院生存率45%。
  • 随访:中位随访3.9年,129例住院幸存者中94例完成随访评估(73%),53例完成健康相关生活质量评估;随访方式为电话访谈。
  • 生存:住院幸存者6个月和12个月生存率分别为89%和85%;ICU存活出院者9.7年估计生存率为68.5%(95%CI 56.9-80.1%)。
  • 健康相关生活质量:中位SF-36总分73;中位SGRQ总分19;中位HAD-D评分2,中位HAD-A评分3。
  • 恢复工作:80%的患者能够恢复工作。

证据类型、等级与局限

  • 证据类型:单中心回顾性注册数据分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该VV ECMO患者分析显示长期生存率较好且健康相关生活质量较高,提示VV ECMO幸存者前景良好。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: There is limited information about the long-term outcome of patients suffering from acute respiratory distress syndrome (ARDS) supported with veno-venous extracorporeal membrane oxygenation (VV ECMO). Most studies focused on short- to mid-term follow-up. We aimed to investigate long-term survival and health-related quality of life (HRQL) in these patients.

METHODS: We report retrospective data from a single-centre registry of patients with severe ARDS treated with VV ECMO at the Interdisciplinary Medical Intensive Care Unit at the Medical Centre, University of Freiburg, Germany, between 10/2010 and 06/2019. Follow-up data of all patients that survived the index hospitalisation were collected by telephone interviews from 02/2020 till 09/2020. Long-term survival, HRQL (Short-Form Health Survey-36 (SF-36), St. Georges Respiratory Questionnaire (SGRQ), Hospital Anxiety and Depression Scale (HADS)) and the return to work rate were documented.

RESULTS: In total, 289 patients were treated with VV ECMO during the study period (median age 55 years, 67% males, hospital survival 45%). After a median duration of 3.9 years, follow-up assessment was complete in 94 of 129 hospital survivors (73%). Fifty-three patients completed the HRQL assessment. Hospital survivors showed a high 6- and 12-month survival rate (89% and 85%, respectively). Estimated survival rate of those discharged alive from ICU was 68.5% (95%-CI 56.9-80.1%) after 9.7 years. These patients reported high levels of HRQL (median SF-36 total score 73) and only few pulmonary (median SGRQ total score 19) and mental limitations (median HAD-D score 2 and HAD-A score 3). In total, 80% of the patients were able to resume employment.

CONCLUSION: This analysis of VV ECMO patients showed favourable long-term survival and high levels of HRQL suggesting promising prospects for VV ECMO survivors.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Rilinger J, Krötzsch K, Bemtgen X, et al. Long-term survival and health-related quality of life in patients with severe acute respiratory distress syndrome and veno-venous extracorporeal membrane oxygenation support. Crit Care. 2021. PMID: 34844654. doi:10.1186/s13054-021-03821-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。